


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+13.69%
-3.81%
-0.54%
-27.11%
+7.00%
VRTX
Vertex Pharma
$460.82
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market

Trading below its fair value
VRTX Price Performance
$477.92 (-3.58%)
$437.01 (+5.45%)
$407.79 (+13.00%)
$503.2 (-8.42%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Eps growth
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Outperform the market
Trading below its fair value
VRTX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
VRTX Street Sentiment is extremely bullish and have positive views on the near-term outlook
VRTX has Low risk level
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Feb 17, 2026
Upgrade
Outperform
Oppenheimer
Feb 13, 2026
Upgrade
Outperform
Oppenheimer
Feb 11, 2026
Downgrade
Neutral
Piper Sandler
Jan 29, 2026
Upgrade
Overweight
Barclays
Jan 23, 2026
Upgrade
Outperform
RBC
What is VRTX current stock price?
What are VRTX stock strengths?
What is VRTX Risk Level?
What is VRTX market cap and volume?
What is VRTX current Stock IQ?
Should I buy VRTX stock right now?
Is VRTX a Strong Buy right now?
What does a 'Strong Buy' rating mean for VRTX?
What does a 'Strong Sell' rating mean for VRTX?
What factors influence VRTX's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
VRTX
Vertex Pharma
Current Price
$460.82

VRTX Price Performance
$477.92 (-3.58%)
$437.01 (+5.45%)
$407.79 (+13.00%)
$503.2 (-8.42%)
VRTX Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Eps growth
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Outperform the market
Trading below its fair value
VRTX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
VRTX Street Sentiment is extremely bullish and have positive views on the near-term outlook
VRTX has Low risk level
Average key support and resistance price levels
Overall Wall Street Rating
VRTX Stock IQ
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market

Trading below its fair value
VRTX Latest Analysis
Vertex Inc. (VERX) Presents at Morgan Stanley Technology Media & Telecom Conference 2026 Transcript.
Wed Mar 4, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript.
Tue Mar 3, 2026
Absci Appoints Ransi Somaratne As Chief Medical Officer . (RTTNews) - Biopharmaceutical company Absci Corp. (ABSI) announced Tuesday the appointment of Ransi Somaratne as Chief Medical Officer. A former Vertex executive Somaratne will spearhead the clinical development strategy and execution for Abscis expanding pipeline of AI-designed
Tue Mar 3, 2026
Vertex Gets Rating Upgrade Earnings Rose Every Quarter This Past Year. Vertex Pharmaceuticals shows improving price performance earning an upgrade to its IBD Relative Strength RatingThe post Vertex Gets Rating Upgrade Earnings Rose Every Quarter This Past Year appeared first on Investor'.s Business Daily.
Mon Mar 2, 2026
Vertex Pharmaceuticalss Options: A Look at What the Big Money is Thinking. Financial giants have made a conspicuous ish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:VRTX) revealed 35 unusual trades.Delving into the details we found 28% of traders were ish while 11% showed bearish tendencies. Out of all the trades we spotted 22 were puts with a value of $847650 and 13 were calls valued at $583233.Expected Price MovementsAfter evaluating the tr
Wed Feb 25, 2026
Why Vertex Stock Zoomed Almost 6% Higher on Thursday. Key PointsIt was the subject of a ish analyst update.
Fri Feb 20, 2026
Heres How Much $1000 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today. Vertex Pharmaceuticals (NASDAQ:) has outperformed the market over the past 15 years by 5.55% on an annualized basis producing an average annual return of 17.22%. Currently Vertex Pharmaceuticals has a market capitalization of $119.99 billion.
Wed Feb 18, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
VRTX Stock trends
VRTX Stock performance
VRTX Stock analysis
VRTX investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.